RxDoctor Payments Data

Gerardo Gamez, MD

Neurology · Fort Myers, FLNPI 1245240829

Payments from drug & device makers

$24,467in general payments, 2019–2025

Across 930 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$1K
  • EMD Serono, Inc.$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$300%
  • Food & beverage$24,29099%
  • Education$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)150$3,306
Amgen(2 entities)62$1,414
EMD Serono, Inc.27$1,385
UCB, Inc.39$1,357
Teva Pharmaceuticals USA, Inc.35$1,096
Acadia Pharmaceuticals Inc50$1,006
Sanofi21$985
AstraZeneca(2 entities)33$977
Novartis39$781
Lundbeck LLC29$739
Neurocrine Biosciences, Inc.29$735
Genentech USA, Inc.18$726
Lilly USA, LLC32$691
Biogen32$683
GE HealthCare33$586
Argenx US, Inc.21$487
Neurelis, Inc.15$475
E.r. Squibb & Sons, L.L.C.4$415
Eisai Inc.14$377
Amneal Pharmaceuticals LLC16$376
SK Life Science, Inc.9$373
Otsuka America Pharmaceutical, Inc.9$372
Pfizer18$312
CSL Behring12$306
Bristol Myers Squibb9$287
Catalyst Pharmaceuticals, Inc.9$284
Sunovion Pharmaceuticals Inc.13$265
TG Therapeutics, Inc.5$234
Merz Pharmaceuticals, LLC8$226
Sumitomo Pharma America, Inc.6$217
MDD US Operations, LLC10$213
Revance Therapeutics, Inc.4$206
Biohaven Pharmaceuticals, Inc.8$201
Johnson & Johnson(2 entities)6$199
Takeda Pharmaceuticals U.S.A., Inc.6$175
Upsher-smith Laboratories LLC12$159
Livanova USA, Inc.1$147
Avion Pharmaceuticals8$133
Adamas Pharmaceuticals, Inc.4$133
Impel Pharmaceuticals Inc.2$130
Supernus Pharmaceuticals, Inc.15$128
Grifols USA, LLC6$116
Abbott1$104
Kyowa Kirin, Inc.6$98
Octapharma USA, Inc.5$94
Tanabe Pharma America, Inc.3$78
Alnylam Pharmaceuticals Inc.3$70
Jazz Pharmaceuticals Inc.3$69
Corium, LLC3$69
Biohaven Pharmaceutical Holding Company Ltd.3$57
Acorda Therapeutics, Inc3$56
Avanir Pharmaceuticals, Inc.4$54
GRT US Holding, Inc.1$34
Amicus Therapeutics, Inc.2$29
Insightec,inc2$28
Aprecia Pharmaceuticals, LLC1$24
Mallinckrodt Hospital Products Inc.1$23
Ipsen Biopharmaceuticals, Inc1$22
Medtronic1$20
C2n Diagnostics, LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,467 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$365,310
Medicare patients
1,054
Services billed
8,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine26$236,349
NuplazidPimavanserin Tartrate20$99,230
RytaryCarbidopa/Levodopa19$39,546
UbrelvyUbrogepant15$17,948
Rivastigmine87$14,906
Emgality PenGalcanezumab-Gnlm14$9,830
Memantine Hcl235$9,152
Aimovig AutoinjectorErenumab-Aooe12$8,557
Carbidopa-Levodopa ErCarbidopa/Levodopa66$8,446
Gabapentin307$5,969
Carbidopa-LevodopaCarbidopa/Levodopa166$5,314
Donepezil Hcl447$5,163
AmantadineAmantadine Hcl52$4,973
Levetiracetam112$4,837
Galantamine ErGalantamine Hbr43$4,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,096$236,34926 claims
Acadia Pharmaceuticals IncNuplazid$1,006$99,23020 claims
Amneal Pharmaceuticals LLCRytary$376$39,54619 claims
AbbVieUbrelvy$3,306$17,94815 claims
PfizerDilantin$312$4,04920 claims
Upsher-smith Laboratories LLCTopiramate$159$1,45287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →